Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.
Alvotech, the Icelandic biosimilars company, has won approval from the European Commission (EC) for the marketing of its adalimumab biosimilar, AVT02, which references Humira. The biosimilar product is cutting edge among approved adalimumab products, as it is high concentration (100 mg) and citrate-free, a formulation that has been capturing market share in the European Union (EU) and United States recently.
The EC approval was officially issued November 15, 2021 and publicized by Alvotech this week. Alvotech may yet face hurdles in commercializing AVT02 in the European Union, where competitive bidding in individual markets, partnership arrangements, and potential opposition from Humira's maker, AbbVie, may cause delays. Alvotech made no mention of a possible EU launch date in its announcement.
An FDA review for possible approval of AVT02 is underway, and Alvotech also must successfully resolve ongoing patent litigation with AbbVie before this product can launch in the United States.
The product received a recommendation for approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in September. The committee's recommendations are pivotal in EC final decisions about medicinal products.
Adalimumab is used in the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, and plaque psoriasis. Adalimumab is a tumor necrosis factor (TNF) inhibitor that in binding to TNF neutralizes its activity and induces apoptosis, or death, of TNF-expressing cells.
"We are thrilled by the EC’s approval of our high concentration biosimilar to Humira," said Róbert Wessman, founder and chairman of Alvotech.
The company has poised itself for rapid expansion of adalimumab biosimilar commercialization in multiple global markets via commercialization deals with multiple companies. Alvotech also has an ustekinumab biosimilar referencing Stelara under development. Clinical studies for the biosimilar candidate, AVT04, were begun in July 2021.
In a recent industry conference, Anil Okay, chief commercial officer for Alvotech, said the company had commercialization deals for its pending biosimilars for upwards of 90 countries.
If launched, AVT02 would become Alvotech’s first commercialized biosimilar. The company was founded in 2013 and has administrative and manufacturing facilities in Europe and under construction in China. The company recently announced a $450 investment from a business consortium and plans to take the company public with a stock offering at an undisclosed future date.
The value of the adalimumab market is sizeable. The product brought in roughly $20 billion in revenues in 2020 for AbbVie. Competitor biosimilars have entered the market in the European Union and in the United States there are 6 approved adalimumab biosimilars scheduled for launch in 2023 and as many as 4 others under development that could launch around that time or later.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.